Biosimilars
Page 1 • 9 itemsTrack global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Biosimilars in Japan: Market Growth and PMDA Regulatory Insights 2024
This article delves into the expanding biosimilars market in Japan, focusing on trastuzumab's role in cancer treatment and the latest PMDA regulatory updates for 2024.
Biosimilar Landscape Japan: PMDA Regulatory Updates & Market Access 2024
Stay informed on Japan's biosimilar landscape with the latest PMDA regulatory updates and market access strategies for 2024, focusing on critical therapies like Adalimumab.
Biosimilar Market in Japan: Growth Trends Post-PMDA Guideline Revisions
The biosimilar market in Japan is experiencing significant growth following PMDA guideline revisions, impacting drugs such as adalimumab for rheumatoid arthritis.
Biosimilar Regulation Japan: Aligning PMDA with EMA and FDA Guidelines
This article examines Japan's biosimilar regulations, focusing on how the PMDA aligns with EMA and FDA guidelines to enhance the approval process for drugs like infliximab.
Biosimilar Landscape in Japan: Impact of PMDA Guideline Updates 2025
This article delves into the impact of the 2025 PMDA guideline updates on the biosimilar landscape in Japan, highlighting significant drugs and their indications.
Biosimilar Market Growth Japan: Impact of PMDA's 2024 Regulatory Update
The PMDA's 2024 regulatory update is set to significantly influence the growth of the biosimilar market in Japan, particularly for drugs like adalimumab.
Biosimilar Landscape Japan: Impact of PMDA Updates & SAKIGAKE Designations
This article delves into the impact of recent PMDA updates and SAKIGAKE designations on the biosimilar market in Japan, particularly for Trastuzumab in breast cancer treatment.
Biosimilar Landscape in Japan: Impact of PMDA Updates & SAKIGAKE 2024
This article delves into the impact of recent PMDA updates and the SAKIGAKE initiative on the biosimilar market in Japan, highlighting implications for drugs like adalimumab.
Biosimilar Market Growth Japan: Impact of PMDA's 2024 Interchangeability Guidelines
This article examines how the PMDA's 2024 interchangeability guidelines will influence the growth of the biosimilar market in Japan, focusing on drugs like Adalimumab.